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A b s t r a c t  
Vinpocetine is a poorly water soluble drug, commonly used in treatment of various cerebral 
insufficiency conditions. The aim of this work was to formulate vinpocetine in the form of orally 
disintegrating tablets (ODTs) and enhance its solubility and dissolution rate. This objective was 
addressed using lyophilization technique of either solid dispersion using polyethylene glycol 4000 
(PEG 4000) or inclusion complex with 2-hydroxypropyl β-cyclodextrin (2HP-β-CD). Differential 
scanning calorimetry (DSC) and fourier transform-infrared (FT-IR) spectroscopy were used to 
characterize the solid state of the prepared solid complex. Tablets were prepared by direct 
compression using 23 factorial design to evaluate the effect of formulation variables (Ac-di-sol 
concentration 5 or 10%, the ratio of soluble polymer 1:1 or 1:3 and binder type 6% w/w Avicel 
PH102 or 6% w/w carboxymethyl cellulose) on release characteristics. Results showed that 
lyophilized ODTs disintegrated within few seconds and had significantly faster dissolution rate (70-
100 % in 5 minutes) compared to the commercial oral tablet (Cavinton®). This was achieved at high 
content of PEG 4000 or 2 HP-β-CD in presence of 10 % w/w Ac-Di-Sol and 6 % w/w Avicel PH102. 
The extent of per oral absorption of vinpocetine was determined in healthy human volunteers using 
randomized crossover design. The relative bioavailability of selected solid dispersion and inclusion 
complex formulations were found to be 171.98 % and 196.06 % respectively. The study indicated 
that complexation of vinpocetine with 2-HP-βCD or dispersion in PEG 4000 followed by 
lyophilization are two successful strategies for enhancing the bioavailability of the drug from ODTs.  
Keywords: Bioavailability; Inclusion complex; Lyophilization; Orodispersible tablets; Solid dispersion; 
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Introduction 
Vinpocetine  is a neurotropic agent [1]. which improves cerebral 
metabolism, increases ATP concentration, reduces blood clotting, 
and a powerful antioxidant [2]. It is superior to other preparations 
used to treat cerebral vascular disorders in that its effect is 
selective. It increases the cerebral blood flow to ischemic areas in 
patients with cerebrovascular disease [3,4]. The very poor aqueous 
solubility of vinpocetine gives rise to difficulties in preparing oral 
pharmaceutical formulation or injectable solution and results in 
variable oral bioavailability. In this study, ODTs containing 
vinpocetine were prepared by direct compression. Solid dispersion 
which is one of the methods that widely and successfully applied to 
improve the solubility, dissolution and consequently the 
bioavailability of poorly soluble drugs was applied. The solid 
dispersion is based on the concept that the drug is dispersed in an 
inert water-soluble carrier at solid state. Several water soluble 
carriers such as methyl cellulose, polyvinyl pyrrolidone and 
polyethylene glycols 4000 and 6000 are used as carriers for solid 
dispersion. Cyclodextrins and their derivatives have been 
frequently used to enhance the bioavailability by  
 
 
increasing the drug solubility, dissolution and/or permeability [5]. 
They also act as penetration enhancers by increasing the drug 
availability at the surface of biological barrier [6]. Vinpocetine is 
exposed to extensive first-pass metabolism to the inactive 
apovincaminic acid [7]. Therefore ODTs of vinpocetine are 
designed to increase drug absorption from oral mucosa and send 
the drug directly to systemic circulation bypassing the first pass 
metabolism of the liver. This will result in increased fraction of 
bioavailable drug and also result in a rapid onset of action via a 
more convenient and comfortable delivery route to the patients, 
especially elderly and those with swelling difficulties. 
Materials and methods 
Materials 
Vinpocetine was generously gifted by Memphis pharmaceutical 
company, Egypt. 2-Hydroxy propyl- ß-cyclodextrin was purchased 
from the Chemical Co., Milwaukee, WI, USA. Polyethylene glycols 
4000, Carboxymethylcellulose (CMC) and Pluronic F127 were 
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purchased from Fluka AG Buchs SG, Switzerland. Avicel PH 102 
(microcrystalline cellulose) was obtained from FMC Corporation, 
Pennsylvania, USA. Magnesium stearate, aspartame, menthol and 
granular mannitol were purchased from El Nasr Chemical and 
Pharmaceutical Company, Egypt.  
Preparation of solid dispersion using lyophilization 
technique 
Freeze drying involved dispersion of appropriate quantities of 
vinpocetine and PEG4000 (water soluble polymer) at ratios of 1:1 
or 1:3 w/w in 1.5 % w/v tartaric acid solution (used as 
cryoprotectant). The mixture was mixed by stirring to obtain clear 
solution. The clear monophase solution was frozen at -20ĈC then 
exposed to freeze drying for 24 hours using Novalyphe freeze drier 
(Novalyphe-NL 500, Savant instruments, Halbrook, NY, USA) The 
resultant freeze dried particles were kept over anhydrous calcium 
chloride in a dessicator for further investigations [8]. The inclusion 
complex was prepared by freeze-drying technique of the drug and 
2-HP-β-CD at molar ratio (1:1) or (1:3) using the same method 
explained above. 
Characterization of prepared solid dispersion 
Differential scanning calorimetry (DSC) 
DSC study was performed for vinpocetine powder, PEG 4000, 
vinpocetine-PEG4000 physical mixture (1:1) and the prepared solid 
dispersion.  Samples (3-4 mg) were hermetically sealed in a flat 
bottomed aluminum pans and heated in the DSC instrument in an 
atmosphere of nitrogen to eliminate the oxidative and pyrrolytic 
effects. A temperature range of 25Ĉ to 300Ĉ C was used and the 
heating rate was 10 ĈC/min.  The DSC of the inclusion complex 
was also determined using DSC-50 instrument (Schimadzu, 
Japan). 
Fourier transform-infrared (FT-IR) spectroscopy 
The FTIR spectra of the pure drug, drug- PEG4000 physical 
mixture (1:1) and the prepared solid mixture as well as the 
inclusion complex were recorded using a Bruker FTIR 
spectrometer (Thermoscientific, Germany) according to the KBr 
disc technique. The FTIR measurements were performed in the 
scanning range of 4000 - 400 cm-1 at ambient temperature.  
Preparation of ODTs 
ODTs were prepared by direct compression technique using a 
single punch tablet press (Model TDP, Shanghai Tianhe China) [9]. 
A full factorial design (23) was applied for the screening study in 
which three factors were used at two levels. These factors were the 
concentration of super disintegrant either 5% or 10% w/w, the ratio 
of water soluble carrier for solid dispersion (PEG 4000) to 
vinpocetine either 1:1 or 1: 3 (w/w) and the type of  binder (Avicel 
PH102  or CMC at a concentration of 6 %w/w).  A combination of  
pluronic127 (2%w/w) as surfactant to increase the wettability of the 
particles, magnesium stearate (0.5% % w/w) as lubricant, 
aspartame (1% w/w) as sweetening agent, and menthol as 
flavoring agent (0.5% w/w) were used for the preparation of ODTs 
as shown in the  Table 1.  All the ingredients were weighed and 
mixed in a mortar and pestle then magnesium stearate was added. 
The blended material was compressed using flatăfaced punch (8 
mm). Vinpocetine ODTs which contain vinpocetine in the form of 
inclusion complex with 2-HP-β-CD were prepared as mentioned 
above, only replacing the solid dispersion carrier of vinpocetine 
with vinpocetine/ 2-HP-β-CD inclusion complex in a molar ratio of 
1:1 or 1:3 as shown in Table 2. All other additives were added with 
the same concentration.  
Pharmaceutical evaluation of the prepared fast 
disintegrating sublingual tables 
Weight variation was evaluated using twenty tablets from each 
formulation selected at random and weighed individually. Average 
weight was calculated and the individual weights were compared 
with the average weight. The weight of not more than two tablets 
must not deviate from the average weight by more than 5% [10]. 
Percentage friability was performed according to British 
Pharmacopoeia by accurately weighing ten tablets from each 
formulation. Then, the tablets were placed in the friabilator drum 
which rotates at 25 rpm for a period of 4 minutes. Subsequently, 
the tablets were brushed and reweighed. The percentage loss in 
weight was calculated and taken as a measure of friability. Tablet 
hardness was evaluated using tablet hardness tester (Dr 
Schleunger Model 6D, Germany). Ten tablets from each 
formulation were examined and the mean hardness value was 
calculated and expressed in Kilograms [11]. The uniformity of 
vinpocetine content in different tablets was determined by crushing 
ten tablets from each formulation and determining the content of 
each tablet individually. The weight of each tablet was dissolved in 
100 ml of 0.1N HCl. The solution was then filtered, properly diluted 
and the absorbance was spectrophotometrically measured at 314.8 
nm and then vinpocetine content of each tablet was calculated (see 
Table 2). 
In-vitro disintegration time 
This test was carried out using six tablets each inserted in each of 
the six cells of the disintegrator, USP Disintegration tester (Hanson 
research, USA). Simulated saliva fluid (SSF) pH= 6.75 kept at 37 μ 
1ĈC  was used as the disintegration medium and the basket was 
raised and lowered at a constant frequency of 30 μ 2 cycles/min. 
The test results were presented as the average of six 
determinations. For each formulation the total time of disintegration 
was measured [12,13]. 
In-vivo disintegration time 
The in vivo disintegration time of the prepared ODTs was 
evaluated in six human volunteers according to code of ethics used 
to treat human volunteers adopted by Beni Suief University.  Each 
of the six subjects was given a coded tablet. Tablets were placed 
on the tongue and immediately the time for disintegration was 
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recorded.  The subjects were asked to spit out the content of the 
oral cavity after tablet disintegration and rinse their mouth with 
distilled water. The swallowing of saliva was prohibited during the 
test, and saliva was rinsed from the mouth after each 
measurement. The test results are presented as mean value μ 
standard deviation figure. 
 
    Table 1: Composition of vinpocetine ODTs prepared by solid dispersion 
  
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
Solid dispersion* 1:1 1:1 1:1 1:1 1:3 1:3 1:3 1:3 
Ac-di-sol 5% 5% 10% 10% 5% 5% 10% 10% 
CMC 6% - 6% - 6% - 6% - 
Avicel PH102 - 6% - 6% - 6% - 6% 
Mint flavor 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 
Aspartame 1% 1% 1% 1% 1% 1% 1% 1% 
Magnesium stearate 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 
Pluronic 127 2% 2% 2% 2% 2% 2% 2% 2% 
Granular Mannitol Quantity sufficient  to make final weight of 200 mg 
   Solid dispersion*: contain  5 mg vinpocetine  and  PEG 4000 (1:1) and (1:3) w/w. 
 
    Table 2: Composition of vinpocetine ODTs prepared by inclusion complexation  
Ingredients F9 F10 F11 F12 F13 F14 F15 F16 
Inclusion complex* 1:1 1:1 1:1 1:1 1:3 1:3 1:3 1:3 
Ac-di-sol 5% 5% 10% 10% 5% 5% 10% 10% 
CMC 6% - 6% - 6% - 6% - 
Avicel PH102 - 6% - 6% - 6% - 6% 
Mint flavor 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 
Aspartame 1% 1% 1% 1% 1% 1% 1% 1% 
Magnesium stearate 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 
Pluronic 127 2% 2% 2% 2% 2% 2% 2% 2% 
Granular Mannitol Quantity sufficient  to make final weight of 200 mg 
  Inclusion complex *: contain 5 mg vinpocetine and 2HP-B-CD of molar ratio (1:1) or (1:3). 
In vitro dissolution of vinpocetine ODTs tablets 
The dissolution of vinpocetine from its tablets was performed in 
200 ml phosphate buffer (pH 6.8), maintained at a temperature of 
37 μ 0.5Ĉ C using the USP Dissolution Tester, Apparatus I 
(Hansson research, USA) at rotation speed of 50 rpm. The 
dissolution test was done by placing a tablet from each formulation 
in the dissolution stainless steel basket. Aliquots from the 
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dissolution medium were withdrawn after certain time intervals. The 
withdrawn samples were filtered through Millipore filter membrane 
of 0.45 μm pore size and analyzed for vinpocetine content by 
measuring their absorbance at 314.8 nm using a UV-
spectrophotometer (Jasco-V 530, Japan).  
In-vivo studies 
The studies were carried out to compare the pharmacokinetics of 
vinpocetine from  formulation (F8 treatment A)  and formulation  
(F16 treatment B)  in comparison to the conventional  Cavinton ® 
tablets (ACAPI , Egypt) and labeled as  treatment C.   A single 
dose of vinpocetine (10mg) was given to the volunteers using 
randomized- single dose three-way (open-label study) randomized 
crossover design (Table 3). Six healthy man volunteers aged 
between 20 to 40 years (median weight: 75 kg and median height: 
183 cm) were chosen. Health status of the volunteers was 
confirmed by complete medical history, physical examination and 
laboratory analysis for complete hematological and biochemical 
examination, all these were carried out at baseline.  None of the 
volunteers had any history of drug or alcohol abuse, nor did they 
have any acute or chronic gastrointestinal, cardiac, vascular, 
hepatic or renal disease. The protocol of the study was conducted 
according to Helsinky agreement protocol and according to the 
requirements of the ethical committee of the faculty of medicine, 
Cairo University, Egypt. The drug was administered orally after 
fasting overnight and washout period of 1 week. Venous blood 
samples (5 mL) were collected into heparinized tubes at the 
following time intervals: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours 
after administration of a treatment. Plasma was obtained by 
centrifugation at 2000 rpm (using centrifuge R32 , Bombay, India) 
for 10 minutes and stored at -20ÀC until the time of analysis. 
 
Table 3: In-vivo randomization plan for two vinpocetine 
formulations F8 and F16 ODTs compared to the conventional 
Cavinton® (10 mg) tablets.  
 
Volunteer 
Number Phase I Phase II Phase III 
1 F8 F16 Cavinton 
2 F16 F8 Cavinton 
3 Cavinton F8 F16 
4 F8 Cavinton F16 
5 F16 Cavinton F8 
6 Cavinton F16 F8 
 
 
 
Chromatographic conditions 
A modified HPLC method for determination of vinpocetine in 
plasma was  adopted [14]. The HPLC apparatus consisted of 
isocratic pump LC-10 AS and a UV/VIS detector SPD-10A 
connected to a C-R6A integrator (Shimadzu, Koyoto, Japan). The 
analytical column was Ponapak C18 HPLC column (4.6 ï 250 I.D 
mm), particle size 125 ÀA (Waters Associates, Ireland). The mobile 
phase composed of methanol: water in ratio of 80:20 (v/v), 
containing 0.1% w/w triethylamine, and pH 7 adjusted with glacial 
acetic acid. The flow rate was 2 ml/min. The detection wavelength 
was set at 274 nm. All assays were performed at ambient 
conditions. 
Plasma analysis 
A calibration curve of vinpocetine in plasma was constructed in the 
concentration range (5-20 ng/ml). Then one mL sample of the 
plasma was mixed with acetonitrile (1 mL) and stock solution of the 
internal standard (ketotifen fumarate) (1 mL). The mixture was 
vortexed for 1 minute and then centrifuged for 10 minutes at 3000 
rpm. The upper layer was separated and transferred to another 
tube then filtered through 0.45 μm Millipore® filter for analysis with 
HPLC. Twenty microliters (μL) of the samples were injected to the 
column for analysis. Spectrophotometric detection at 274 nm was 
interpreted in the form of the reported peak areas. The recovery 
(20-600 ng/mL) varied between 97.58 and 100.23 %.   
Pharmacokinetic analysis 
Pharmacokinetic parameters were obtained from plasma data 
following administration of two treatments and control to each 
subject using WinNonlin® (version 1.5, Scientific consulting, Inc., 
Cary, NC, USA). Non-compartmental analysis was adopted for 
calculation of Cmax (ng/mL) and tmax (h); the observed maximal 
drug concentration and the time needed to reach this concentration 
respectively. The relative bioavailability was calculated as (AUC test 
/ AUC standard) x100. 
Statistical analysis 
An analysis of variance (ANOVA) test was performed for 
untransformed data for the pharmacokinetic parameters Cmax, tmax, 
AUC0ăt, and t 1/2 using the software SPSS 11.0 (SPSS Inc., 
Chicago, USA) at p-value (p ª 0.05).  
Results and discussion 
Differential scanning calorimetry (DSC) 
The possible interaction between the drug and the soluble carrier 
(PEG) was studied by DSC (Figure. 1).  Pure vinpocetine powder 
showed a melting endotherm at 152.8 ĈC and the scan of PEG 
4000 showed a broad endotherm at 62.5ĈC. It was clear that the 
sharp endothermic peak of the drug, became shorter in the 
thermograms of the physical mixtures which may be attributed to 
the reduced purity of samples after mixing[15].  The DSC scan of 
the solid dispersion shows the absence of a drug peak as shown in 
 Figur
and 
PEG
(vinp
comp
demo
wate
in th
inclu
repo
hydro
Fou
Analy
poss
the d
show
show
chara
in vin
FTIR
peak
stretc
(Figu
the f
majo
FTIR
intera
shifts
[19]. 
phys
Figur
abso
OH s
(C-H
A sh
be a
The 
comp
vinpo
in go
hand
show
phys
the d
with 
the in
syste
cavit
The 
by m
phar
e.1d, suggestin
in an amorphou
 4000 matrix[1
ocetine/ HP-ßC
lex are shown
nstrated an end
r loss. The char
e complex th
sion between d
rted by Liu and
chloride with H
rier-Transform
sis by FTIR s
ible interaction 
rug, PEG 4000
n in Figure. 3. 
s its character
cteristic should
pocetine and 30
 spectra of PE
s at 2950ă2750
hing). FTIR sp
res. 3c and 3d)
unctional groups
r interaction bet
 spectroscopy o
ction between 
 in the drug a
The IR spectr
ical mixtures a
e. 4. The spec
rption bands at
tretching vibrati
 aliphatic stretc
orter band appe
scribed to the h
spectra of the ph
onents spectra
cetine and 2HP
od agreement w
, the IR spectra
ed considerable
ical mixtures as
issociation of t
crystalline drug
tensity of the d
ms, might be 
y [22].  
weight uniformit
ore than 5 %
macopoeial limit
g that  vinpocet
s form or is pre
6]. DSC therm
D), 1:1 physic
 in Figure.2. T
othermic peak 
acteristic peak 
ermogram. Thi
rug and the cy
 Zhu [17] for in
P-β-CD. 
 infrared spe
pectroscopy wa
between drug a
, physical mixtu
The spectrum o
istic peaks at 
er of carbonyl 
00-2840 cm-1 a
G 4000 (Figure
 cm-1(CăH stretc
ectra of physica
 show no subst
. The peaks are
ween vinpocetin
f inclusion com
vinpocetine an
bsorption spect
a of vinpocetine
nd the inclusio
tra of HP-ß-CD
 3500-3300 cm
on [20], the vibr
hing) appeared 
ared in the reg
ydrated bonds 
ysical mixtures
 indicating the a
-ßCD in the ph
ith the work of
 of (vinpocetine
 differences wh
 shown in Figure
he intermolecul
 molecules. The
rug aromatic stre
due to its rest
y test showed th
, indicating th
s for weight var
Kharsh
ine was molecu
sent as a solid
ograms of pu
al mixtures and
he thermogram
around 60 ÀC co
of the drug tota
s result confir
clodextrin. Sim
clusion complex
ctroscopy 
s carried out 
nd PEG 4000. F
re and the solid
f pure vinpoceti
1716.34 cm-1 
stretching band 
ssigned to arom
. 3b) shows the
h), and 1468.84
l mixture and s
antial shifting of
 only broadene
e and hydroph
plex was used
d HP-ß-CD. T
rum occur upon
, (vinpocetine/
n complex, ar
 illustrated an
-1 correspondin
ation of ăCH an
in the region 29
ion 1650-1640 c
within cyclodex
 were the super
bsence of inter
ysical mixture. 
 Fernandes  [21
/ 2HP-ßCD) inc
en compared w
. 4d. This can b
ar hydrogen bo
 broadening a
tching band ob
riction within th
at none of the t
at all formulati
iation. 
 
oum et al. Int
larly dispersed 
 solution inside 
re vinpocetine, 
 the inclusion 
 for HP-ßCD,
rresponding to 
lly disappeared 
med complete 
ilar effect was 
es of prazocin 
to assess any 
TIR spectra of 
 dispersion are 
ne (Figure. 3a) 
which has the 
(C=O) present 
atic stretching. 
 characteristic 
 cm-1 for (CăO 
olid dispersion 
 the position of 
d, indicating no 
ilic carriers[18]. 
 to confirm the 
he changes or 
 complexation
2HP-ßCD), 1:1 
e illustrated in 
 intense broad 
g to the free ă
d ăCH2 groups 
50-2600 cm-1. 
m-1, that could 
trin molecules. 
position of pure 
action between 
This result was 
]. On the other 
lusion complex 
ith those of the 
e explained by 
nds associated 
nd decrease in 
served in these 
e cyclodextrin 
ablets deviated 
ons fulfills the 
ernational Jo
 
 
Figure
b) Pur
 
Figure
cyclod
c) Phy
urnal of Drug 
. 1: DSC of sol
e PEG4000 c) P
.2: DSC therm
extrin solid syst
sical mixture an
Delivery 5 (2
PA
id dispersion sy
hysical mixture
ograms of vin
ems. a) Pure v
d d) Inclusion co
 
) 167-176 [2
GE | 171 |
stems; (a) Pure
  and d) Solid di
pocetine/2-Hydr
inpocetine; b) P
mplex 
013] 
 vinpocetine ; 
spersion 
oxyypropyl-β-
ure HP-β-CD; 
 
 
 Figur
vinpo
c) Ph
 
Figur
syste
mixtu
Pha
table
e.3: FTIR pat
cetine, b) PEG4
ysical mixture a
e.4: FTIR patt
ms. a) Pure v
re and d) Inclus
rmaceutical 
ts 
 
 
terns of solid 
000;  
nd d) Solid disp
erns of vinpoce
inpocetine; b) 
ion complex 
characterizat
Kharsh
dispersion sys
ersion 
 
tine-2HP β-cyc
Pure HP-β-CD
ion of vinpoc
oum et al. Int
tem; a) Pure 
lodextrin solid 
;  c) Physical 
etine ODTs 
ernational Jo
 
 
 
All for
which 
hardn
friabili
for dif
more t
In-vit
The in
w/w C
disinte
contai
may b
formu
disinte
Ac-di-
notice
corres
In-vit
The p
There
that ha
23]. T
from O
illustra
dissol
comm
profile
techni
w/w d
polym
compa
The d
20 % 
nature
dissol
the de
solid 
which 
wetab
system
showe
the 2
mentio
drug 
operat
the dr
highes
the in-
urnal of Drug 
mulations were
were reported 
ess in the rang
ty was in the ra
ferent formulatio
han 95 % from 
ro and in-vivo
-vitro disintegra
MC with 5 % 
gration time (m
ning 6% w/w Av
e attributed to d
lations F4, F8
gration time du
sol (10 % w/w)
d that in-vivo dis
ponding in-vitro
ro dissolution
H of the mouth
fore, in the diss
s a pH of 6.8 μ
he cumulative 
DTs compare
ted in Figures.
ution profiles o
ercial drugs are
 of vinpocetine 
que. It is obviou
rug to polymer e
er.  F8 exhibi
red with the o
issolution of the
in 30 minutes. 
 of the drug an
ution rate of the
crease in degre
dispersion and 
together cont
ility of the drug
 formulation of 
d that the rate 
HP-β-CD ratio 
ned by Ribeiro 
dissolution to 
ing locally in th
ug particles [25]
t dissolution rat
vivo study. 
Delivery 5 (2
PA
 evaluated for 
in Table 3 and 
e of 5.11 ă 8
nge of 0.31-0.8
ns was highly 
all formulations.
 disintegratio
tion study show
w/w Ac-di-sol 
ore than 3 m
icel PH102 with
isintegration pro
, F12 and F
e to the presenc
 with Avicel PH
integration time
 disintegration ti
 studies 
 saliva ranges
olution studies,
 0.5 was adopte
vinpocetine dis
d to the marke
 5 and 6.    R
f the prepare
 observed. Figu
from the ODTs
s that the table
xhibit higher dis
ted the highes
ther tested tab
 marketed vinp
This could be 
d poor wettabil
 solid dispersion
e of crystallinity
the surface ac
ributed to the
 [24]. The dis
the drug with H
and extent of d
increased. Thi
et al. [17] who 
the solubiliza
e aqueous hyd
. Formulations F
es after 5 minu
) 167-176 [2
GE | 172 |
various physica
4. All the table
.55 kg/cm2. Th
9 %. Drug cont
uniform and wa
  
n time 
ed that ODTs c
(F1 and F9) s
inutes) compa
 5 % w/w (F2 a
perties of Avice
16 possessed
e of the high co
102 (6 % w/w
 values were sh
mes for all form
 between 5.6 a
 simulated saliv
d as a dissolutio
solved as a fun
ted product (C
emarkable diffe
d ODTs and 
re 5 illustrates t
 prepared by so
ts prepared ac
solution rate th
t extent of dru
lets of different
ocetine formula
due to the high
ity. The  improv
 system may b
 of the drug due
ting properties 
  increased s
solution profile 
P-β-CD illustrate
rug release was
s finding agree
attributed this im
tion action of
rodynamic laye
8 and F16 dem
tes so they wer
013] 
l parameters 
ts maintained 
e percentage 
ent calculated 
s found to be 
ontaining 6% 
howed longer 
red to ODTs 
nd F9), which 
l PH102. The 
 the lowest 
ncentration of 
). It was also 
orter than the 
ulation. 
nd 7.6 units. 
a fluid (SSF) 
n medium [3, 
ction of time 
avinton®) are 
rences in the 
those of the 
he dissolution 
lid dispersion 
cording to 1:3 
an 1:1 drug to 
g dissolution 
 formulations. 
tion was only 
 hydrophobic 
ement in the 
e attributed to 
 to lyophilized 
of the carrier 
olubility and 
of the binary 
d in Figure. 6 
 increased as 
s  with that 
provement in 
 cyclodextrin 
r surrounding 
onstrated the 
e selected for 
Kharshoum et al. International Journal of Drug Delivery 5 (2) 167-176 [2013] 
 
PAGE | 173 |
 
 
Table 4: Pharmaceutical evaluation data of the prepared vinpocetine ODTs prepared by solid dispersion  
 
Formula 
Number 
Average 
Weight (mg) μ 
S.D* 
% 
Friability 
Hardness (Kg μ 
S.D.*) 
In-vivo Disintegration 
Time μS.D.* 
(sec.) 
In-vitro 
Disintegration 
Time μS.D.* 
(Sec.) 
% Content 
Uniformity 
F1 103.36 μ0.12 0.316 7.81 μ 0.720 > 3min > 3min 102.5μ0.93 
F2 99.13 μ0.09 0.471 7.52 μ 0.811 8711μ6.92 116.17μ9.91 94.31 μ2.8 
F3 100.33 μ0.07 0.708 7.07 μ 0.613 44.6μ5.36 55.15μ6.29 112.01μ0.99 
F4 101.69 μ0.19 0.625 8.55μ 0.441 37.15μ6.20 42.39μ6.47 99.03 μ1.95 
F5 104.77 μ0.049 0.870 6.99μ 0.860 98.6μ4.82 106.50μ10.73 105.81μ2.0 
F6 102.29 μ0.39 0.711 6.37 μ 0.815 61.71μ4.76 74.15μ6.52 92.94 μ1.24 
F7 100.75μ0.24 0.835 5.73 μ 0.449 34.79μ3.76 40.6μ4.25 90.48 μ1.49 
F8 103.44μ0.39 0.791 5.51 μ 0.742 27.68 μ1.55 31.71μ5.75 103.05μ2.75 
 
                Table 5: Evaluation data of the prepared vinpocetine ODTs prepared by inclusion complexation  
 
Formula Number Average 
Weight (mg) μ S.D* % Friability 
Hardness (Kg 
μ S.D.* 
In-vivo 
Disintegration 
Time μ S.D.* 
(sec.) 
In-Vitro Disintegration 
Time μ S.D.* 
(Sec.) 
 % Content Uniformity 
F9 100.10μ0.53 0.795 7.11 μ 0.130 > 3min > 3min 104.6 μ0.81 
F10 102.54μ1.15 0.405 6.01 μ 0.328 83.11μ3.02 96.17μ3.11 98.61μ1.472 
F11 99.18μ0.99 0.779 6.87 μ 0.453 64.6μ5.36 71.15μ6.20 102.71μ2.01 
F12 101.58μ1.37 0.921 6.11μ 0.157 29.19μ2.89 33.27μ6.38 96.25 μ0.92 
F13 99.91μ1.15 0.779 7.93μ 0.536 89.27μ4.14 112.49μ6.59 103.62μ2.57 
F14 98.18μ2165 0.891 7.89 μ 0.079 70.48μ8.50 84.558μ4.12 101.15μ0.98 
F15 102.47μ0.93 0.55 4.87 μ 0.421 37.25μ4.82 44.95μ5.28 98.34μ1.49 
F16 99.33μ1.97 0.611 5.11 μ 0.130 18.37μ5.43 23.20μ6.615 101.55μ3.11 
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Figure.5: In-vitro dissolution profiles of vinpocetine from ODTs 
prepared by solid dispersion in phosphate buffer pH 6.8 at 37 μ 
0.5ÀC 
 
Figure.6: In-vitro dissolution profiles of vinpocetine from ODTs 
prepared by inclusion complex in phosphate buffer pH 6.8 at 37 μ 
0.5ÀC 
In-vivo absorption studies 
The mean plasma concentrationătime courses from vinpocetine 
following per oral administration of ODT F8, F16 and Cavinton are 
illustrated in Figure. 7. All the pharmacokinetic parameters were 
evaluated using WinNonLin® Professional. Vinpocetine was 
detected in plasma immediately after 15 minutes from 
administration of the ODT in six subjects. This rapid onset 
indicated superiority of absorption from per oral route using ODTs. 
Conversely, vinpocetine appeared in plasma after 30 minutes for 
subjects received the regular oral marketed Cavinton® tablets. The 
mean Cmax estimated from F8 and F16 were 34.41 μ 8.24 ng/mL 
and 39.18 μ 8.7130 ng/mL respectivel,while it was 25.20 μ 8.09 
ng/mL for Cavinton® tablets. The differences between the three 
treatments for Cmax appeared to be statistically significant (p < 
0.05).  The mean AUC0ăt estimated from ODTs which reflects the 
total amount of drug absorbed over the 10 hrs time period, t max 
and t 1/2 were determined (see Table 6). The relative bioavailability 
of F16 was 196.04 compared to 171.37% for F8 when Cavinton® 
tablets were taken as the reference standard. 
The higher Cmax, faster tmax and the improved bioavailability 
observed for F8 and F16 than the commercially available 
conventional tablet (Cavinton®) may be attributed to rapid 
disintegration and dissolution of the drug in saliva even with the 
absence of water.  Moreover, in case of ODTs, the drug  partially 
absorbed through the mucosal membrane and consequently  the 
bioavailability was increased [26]. Furthermore, the  rapid 
absorption of vinpocetine from the buccal mucosa, pharynx and 
esophagus as the saliva passes down into the stomach (pregastric 
absorption) led to a decreased pre-systemic biotransformation [27]. 
The increased relative bioavailability of F16 compared F8 might be 
due to the effect of  2-HP-βCD incorporated product which have 
the ability to interact with macromolecules of mucosal membrane 
more efficiently causing marked improvement in drug absorption 
[28, 29]. 
 
 
 
 
Figure.7: Plasma concentration of vinpocetine following oral administration of Cavinton ® tablets and per oral administration of F8 and  F16 
ODTs. 
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The ability of 2-HP-β CD to augment the extent and stability of 
supersaturated solutions of various poorly water soluble drug 
candidates with consequent improvement of their oral 
bioavailability has been assessed by Vandecruys et al. [30].  An 
additional factor that could contribute to the improved oral 
absorption and enhanced bioavailability of drugs by hydrophilic 
cyclodextrins is the increased permeation of drug molecules across 
the membrane lipid bilayers, as a result of their enhanced 
availability at the biological barrier and the alteration of the 
membrane fluidity [31-33]. 
 
Table 6: Pharmacokinetic parameters of vinpocetine following oral administration of a single dose (10 mg) of marketed formulation (Cavinton® 
tablets) and selected ODTs formulation (F8) and (F16) 
 
Conclusion 
From the present study it can be easily demonstrated that, orally 
rapid disintegrating tablets of vinpocetine prepared by freeze-
drying technique is considered a successful formulation 
methodology. This method resulted in improved water solubility 
characteristics of vinpocetine and maximized its bioavailability 
compared to the marketed product. Vinpocetine ODTs prepared 
from inclusion complex with 2-HPβCD showed better results 
compared with those prepared by solid dispersion technique. 
Therefore; the study suggests that the developed ODT formulation 
F16 may be a better alternative to conventional oral formulation of 
vinpocetine with possibility of reduction of the dose.  
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